News on Medial

EndureAir raises $2.85 Mn led by IAN Alpha Fund

EntrackrEntrackr · 3m ago
EndureAir raises $2.85 Mn led by IAN Alpha Fund
Medial

EndureAir raises $2.85 Mn led by IAN Alpha Fund EndureAir Systems, a deep-tech UAV (Unmanned Aerial Vehicle) and aerial robotics firm, has raised Rs 25 crore (about $2.85 million) in funding led by IAN Alpha Fund, with participation from IAN Angel Fund. The proceeds will be used to strengthen its UAV capabilities for the defense ecosystem, expand into enterprise markets, and accelerate the development of next-generation high-altitude logistics and aerial robotics platforms. Founded in 2018 by Dr. Abhishek along with his former students Rama Krishna and Chirag Jain, EndureAir designs and manufactures rugged, indigenous UAVs for logistics, defense, surveillance, and disaster response. Unlike drone assemblers, the brand develops both hardware and software fully in-house, leveraging over 15 years of rotorcraft research and backed by 8 patents in flight dynamics and autonomy. EndureAir’s UAV portfolio includes: Sabal, a heavy-lift logistics drone family (10–70 kg payloads) already inducted by the Indian Army’s Eastern Command; Vibhram, a long-endurance UAV that powered Telangana’s Medicine from the Sky vaccine delivery program; and Alakh, a nano-UAV series deployed in critical rescue missions from Chamoli cloudburst to the Turkey earthquake. It is also co-developing high-altitude logistics drones with Bharat Electronics Limited (BEL) and piloting missions in Bhutan with Druk Holding & Investments (DHI). The Noida-based startup competes with players like IdeaForge, Garuda Aerospace, and NewSpace Research.

Related News

IAN Group marks final close of $100 Mn Alpha Fund

EntrackrEntrackr · 12d ago
IAN Group marks final close of $100 Mn Alpha Fund
Medial

IAN Group marks final close of $100 Mn Alpha Fund Early-stage investment platform IAN Group has completed the final close of its second venture capital vehicle, the IAN Alpha Fund, with a corpus of $100 million. The fund aims to back early-stage, tech-enabled startups addressing major industry and societal challenges. Its investment focus spans sectors such as artificial intelligence, space tech, semiconductors, climate, healthcare, and other frontier domains. The Alpha Fund saw backing from a mix of institutional and government-linked investors, including funds like the Self-Reliant India Fund, SIDBI Fund of Funds for Startups, ACE Fund, and Odisha Startup Growth Fund, along with insurance and family-office investors. According to IAN, several of its initial portfolio companies, 10 to 12 so far, are led by first-generation founders based in tier-II and tier-III cities. IAN enables entrepreneurs to raise from Rs 50 lakhs to Rs 50 crore on a single platform, along with mentoring and global market access. The Group’s investment thesis has been to invest in startups in emerging sectors led by exceptional founders solving real problems or building for India’s strategic imperatives, while giving exceptional investor returns. Over the last 19 years, it claims to have consistently returned capital with multiples in high double digits. The fund follows IAN’s broader vision of supporting startup growth across geographies and sectors, with a stated aim to help founders in smaller cities get the same opportunities as those in major urban centres. In August this year, IAN Group had also appointed Chintan Thakkar as Group CEO of IAN Group.

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 5m ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Neuroscience startup BrainSight AI raises $5 Mn

EntrackrEntrackr · 11m ago
Neuroscience startup BrainSight AI raises $5 Mn
Medial

Snippets Neuroscience startup BrainSight AI raises $5 Mn Deep-tech neuroscience startup BrainSight AI has raised $5 million in a pre-Series A funding round led by IAN Alpha Fund, along with participation from IvyCap Ventures, Silver Needle, and its existing investors. The fresh funds will be utilized to expand its presence in India, increasing reach in Tier I and Tier II cities, making a foray into Africa, Southeast Asia, the US, and allied markets, and enhancing R&D capabilities, BrainSight said in a press release. Co-founded in 2019 by Laina Emmanuel and Rimjhim Agrawal, BrainSight AI aims to enable greater precision in the diagnosis and treatment planning of neuro-oncological and neuropsychiatric disorders. The platform combines artificial intelligence and neuroscience to enable precision in neurological and psychiatric investigations for accelerated patient outcomes. According to BrainSight, its platform products include Voxelbox, which provides clinicians with access to an fMRI processing engine and machine-learning models; and Snowdrop, a patient care app that enables compliance with treatment schedules and builds patient profiles. Currently, BrainSight AI asserts that it collaborates with over 40 leading hospitals across India, particularly in neurosurgery and radiology departments, focusing on brain tumor cases. The company is now expanding its solutions to neurological and psychiatric disorders, paving the way for a more holistic approach to brain care. BrainSight AI helps to understand how the physiology of the brain correlates to its functions by mapping macro-scale neural connections in the brain to enable precise diagnosis and prognosis of neuro-oncological and neuropsychiatric disorders.

Download the medial app to read full posts, comements and news.